# ADULT COMMUNITY-ACQUIRED PNEUMONIA (CAP)
PSMID 2020 | Immunocompetent Adults

---

### 1. RISK STRATIFICATION

**LOW RISK**
* RR <30 | HR <125 | SBP ≥90 | DBP >60
* Normal mentation, no aspiration, stable comorbidities
  → **Outpatient**

**MODERATE RISK**
* Any unstable vital sign, acute confusion, aspiration risk, or unstable comorbidity
  → **Admit (Ward)**

**HIGH RISK**
* Severe sepsis / septic shock **OR** need for mechanical ventilation
  → **ICU**

---

### 2. EMPIRIC ANTIBIOTICS (START ≤4 HRS)

#### LOW RISK – NO COMORBIDITIES
* **Amoxicillin** 500 mg PO **q8h**
  *OR*
* **Azithromycin** 500 mg PO **OD** (Day 1), then 250 mg PO OD (Days 2–5)
  *OR*
* **Clarithromycin** 500 mg PO **q12h**

---

#### LOW RISK – WITH STABLE COMORBIDITIES
* **Amoxicillin-clavulanate** 625 mg PO **q8h**
  *PLUS*
  * **Azithromycin** (as above)
    *OR*
  * **Doxycycline** 100 mg PO **q12h**

*Alternative:*
* **Cefuroxime axetil** 500 mg PO **q12h** + macrolide

---

#### MODERATE RISK (NON-MDRO)
* **Ampicillin-sulbactam** 1.5–3 g IV **q6h**
  *OR*
* **Ceftriaxone** 1–2 g IV **OD**
  *PLUS*
* **Azithromycin** 500 mg IV/PO **OD**

---

#### HIGH RISK (NON-MDRO)
* **Ceftriaxone** 2 g IV **OD**
  *PLUS*
* **Azithromycin** 500 mg IV **OD**

*Alternative:*
* **β-lactam + Respiratory FQ**
  * **Levofloxacin** 750 mg IV/PO **OD**

---

### 3. MDRO RISK – ADD / MODIFY

**MRSA RISK**
* **Vancomycin** 15–20 mg/kg IV **q8–12h** (target trough 15–20)
  *OR*
* **Linezolid** 600 mg IV/PO **q12h**

**ESBL RISK**
* **Ertapenem** 1 g IV **OD**
  *OR*
* **Meropenem** 1 g IV **q8h**
  (+ macrolide or levofloxacin)

**PSEUDOMONAS RISK**
* **Piperacillin-tazobactam** 4.5 g IV **q6h**
  *OR*
* **Cefepime** 2 g IV **q8–12h**
  *OR*
* **Ceftazidime** 2 g IV **q8h**
  (+ azithromycin or levofloxacin)

---

### 4. ANTIVIRAL (INFLUENZA SEASON)
* **Oseltamivir** 75 mg PO **q12h x 5 days**
  → Start empirically in **high-risk CAP** with ILI if testing delayed

---

### 5. DIAGNOSTICS (DO NOT OVERDO IT)
* **Low risk:** No routine cultures
* **Moderate/High risk:** Blood cultures ± sputum Gram stain/culture
* **Legionella urine Ag:** Consider (severe CAP)
* **Procalcitonin:** Not for diagnosis; may assist in stopping antibiotics

---

### 6. DURATION & STEP-DOWN
* **Minimum 5 days**
* Stop when: afebrile ≥48 h + stable vitals + improving clinically
* IV → PO once stable (same class preferred)

---

### 7. FOLLOW-UP
* **No routine repeat CXR** if improving
* **Repeat CXR at 6–8 weeks** (rule out malignancy/alternative dx)

---

**CLINICAL PEARL:**
If not better at **72 hours**, reassess diagnosis (TB, fungi, PE), complications, or resistance before escalating antibiotics.